GLMD vs. NEUP, TRAW, CHRO, HCWB, KPRX, GELS, TLPH, IBIO, AIMD, and ACXP
Should you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Neuphoria Therapeutics Inc. - Common Stock (NEUP), Traws Pharma (TRAW), Chromocell Therapeutics (CHRO), HCW Biologics (HCWB), Kiora Pharmaceuticals (KPRX), Gelteq (GELS), Talphera (TLPH), iBio (IBIO), Ainos (AIMD), and Acurx Pharmaceuticals (ACXP). These companies are all part of the "pharmaceutical products" industry.
Galmed Pharmaceuticals vs.
Neuphoria Therapeutics Inc. - Common Stock (NASDAQ:NEUP) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.
Neuphoria Therapeutics Inc. - Common Stock's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.
15.9% of Neuphoria Therapeutics Inc. - Common Stock shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 0.7% of Neuphoria Therapeutics Inc. - Common Stock shares are held by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Galmed Pharmaceuticals has lower revenue, but higher earnings than Neuphoria Therapeutics Inc. - Common Stock.
Neuphoria Therapeutics Inc. - Common Stock has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.
Neuphoria Therapeutics Inc. - Common Stock presently has a consensus target price of $21.00, suggesting a potential upside of 311.76%. Given Neuphoria Therapeutics Inc. - Common Stock's stronger consensus rating and higher possible upside, equities research analysts clearly believe Neuphoria Therapeutics Inc. - Common Stock is more favorable than Galmed Pharmaceuticals.
In the previous week, Galmed Pharmaceuticals had 3 more articles in the media than Neuphoria Therapeutics Inc. - Common Stock. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 1 mentions for Neuphoria Therapeutics Inc. - Common Stock. Neuphoria Therapeutics Inc. - Common Stock's average media sentiment score of 1.89 beat Galmed Pharmaceuticals' score of 0.22 indicating that Neuphoria Therapeutics Inc. - Common Stock is being referred to more favorably in the media.
Galmed Pharmaceuticals received 441 more outperform votes than Neuphoria Therapeutics Inc. - Common Stock when rated by MarketBeat users. However, 100.00% of users gave Neuphoria Therapeutics Inc. - Common Stock an outperform vote while only 62.52% of users gave Galmed Pharmaceuticals an outperform vote.
Summary
Neuphoria Therapeutics Inc. - Common Stock beats Galmed Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get Galmed Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galmed Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:GLMD) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy GLMD Stock Free GLMD Stock Alerts